20.02.08 Interpretation of CNVs Flashcards

1
Q

What is a CNV

A
  • Copy number variant
  • Segment of DNA that is present at a variable copy number in comparison with a reference genome. Can be gains or losses.
  • Commonly larger than 1kb, although due to advances in technology, now typically >50bp
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Categories of CNVs

A
  • Benign= likely to be of no clinical significance.
  • Uncertain clinical significance= not previously reported or if reported, insufficient evidence for its classification
  • Pathogenic= involve regions of known clinical significance or large changes.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Basics of CNV classification

A
  • Assessment of regions involved in comparison to internal and external databases and literature.
  • Comparison to clinical indication of patient
  • Parent follow up
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Analysis software examples

A

-Bluefuse or cytosure. Align data with annotation tracks of external and internal databases. Disease and control population datasets.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Why must caution be used for public datasets

A
  • Different platforms used. Identical CNVs could be reported at different sizes.
  • Sex of individuals not always given. CNV on X chromosome could be reported as benign in female when pathogenic in males
  • Majority of CNVs in large population studies have not been validated
  • Factors like incomplete penetrance/variable expressivity, age-of-onset, parent of origin imprinting effects are not considered.
  • CNVs reported in multiple publications may represent the same individual.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What database is used for control population data

A
  • DGV (database of genomic variants)
  • Curated collection of CNVs.
  • Comprises >2.5 million entries from >22,300 genomes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Databases for gene content information

A
  • OMIM (online mendelian inheritance in man)= catalogues all human diseases with their gene content.
  • OMIM morbid genes= List of genes linked to a particular disorder
  • ENSEMBL= gene database
  • HGNC (Hugo gene nomenclature committee)
  • Haploinsufficiency scores. Predicted probability of exhibiting haploinsufficiency
  • ClinGen dosage sensitivity map. Database of dosage sensitive genes/regions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Databases for pathogenic CNVs

A
  • Decipher (database of chromosome imbalances and phenotypes in humans using ensembl resources). Breakpoints of previously recorded imbalances with phenotypic information.
  • ClinVar
  • ISCA database
  • ECARUCA
  • Internal lab databases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Are larger CNVs more likely to be pathogenic?

A
  • Yes.

- Although very large CNVs can be benign. Need to consider the content (gene rich, repetitive elements etc).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Assessing if a CNV is pathogenic

A
  • is the phenotype associated with haploinsufficiency? A gain may have effect
  • Disorders due to gain of function variants rather than dosage imbalances (FGFR1 in skeletal dysplasia)
  • Gains involving part of a gene may cause disruption
  • Dels associated with recessive disease may suggest a mutation on the other allele
  • Variants only involving introns could still affect gene function
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Are benign CNVs common in general population

A
  • Yes
  • 4.8-9.5% of genome is copy number variable
  • 100 genes can be completely deleted with no phenotypic consequences
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the criteria for a benign CNV

A
  • High frequency in population databases (>1%)
  • CNV overlaps, similar to one seen in healthy population dataset
  • No known clinical associations (absence of gene content)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the criteria for a pathogenic CNV

A
  • Previously reported in literature/ disease database
  • Gene content= genes with a clinical association relevant to phenotype and mode of inheritance.
  • Larger CNVs more likely to be pathogenic (often >1Mb)
  • Often de novo
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Who created a list of criteria to assess pathogenicity of CNVs

A

-ISCA (International Standards for Cytogenomic Array) 2010

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What follow up studies can be done

A

-Parental studies. To determine if de novo or inherited from a parent with a balanced translocation (fish and metaphase analysis can aid)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Examples of CNVs with variable expressivity/ incomplete penetrance

A
  • 1q21.1, 16p11.2, 15q13.3

- Enriched in affected individuals compared to healthy pop, but can be seen in normal parents.

17
Q

What is the diagnostic yield of CNVs in prenatal setting

A
  • 2.4% for karyotypes with any referral reason

- 7% for karyotype with abnormal ultrasound scans

18
Q

Which research study helped establish bp guidelines for reporting CNVs in prenatal setting

A

-EACH study.

19
Q

According to BP guidelines, when is chromosome microarray indicated in prenatal setting

A

-Abnormal ultrasound scan or nuchal translucency of >3.5mm at 11-14 weeks

20
Q

According to BP guidelines, which variants are reported in prenatal setting

A
  • Variants that will inform the management of pregnancy or for the family.
    1. Pathogenic variants related to indication.
    2. Neuro-susceptibility loci with increased risk of severe phenotype or anomalies in scan
    3. Incidental findings that could alter management of family (e.g. cancer predisposition genes, carrier status of recessive/x-linked disorders)
21
Q

According to BP guidelines, which variants are not reported in prenatal setting

A
  • Variants not linked to phenotype of the pregnancy
  • Variants with no clinically actionable consequences for child/family (VUS)
  • Low penetrance loci
  • Unsolicited pathogenic variants where there is no available intervention.
22
Q

Other difficulties with chromosome microarray testing in prenatal setting

A
  • Phenotyping of fetus is limited.
  • Mosaic CNVs. Could be pseudomosaicism or confined placental mosaicism. Need a confirmatory sample. Most clinical data is obtained postnatally thus are liable to postnatal ascertainment bias.
  • 25-30% of prenatal arrays will identify CNVs needing follow up studies.
23
Q

Aims of the best practice guidelines

A

-To provide more consistent interpretation.